Strengths and prices
| Strength | Price per vial | Availability | Batch | |
|---|---|---|---|---|
| 10 mg | $30.00 | In stock | — |
Every vial carries its batch code and a QR that opens the certificate of analysis for that exact batch. No account is needed to read one.
What it is
VIP (vasoactive intestinal peptide) is a naturally occurring neuropeptide of 28 amino acids in the secretin and glucagon family. The synthetic form is also called aviptadil.
Identity
| Type | Synthetic peptide, 28 amino acids, C-terminal amide |
|---|---|
| Molecular weight | About 3,326 g/mol |
| CAS number | 40077-57-4 |
VIP is a linear peptide of 28 amino acids, His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2, with a free N-terminus and an amidated C-terminus; the human sequence is the same as the porcine peptide first isolated. Its molecular weight is about 3,326 g/mol (CAS 40077-57-4). No molecular formula is given here, because the public chemical database record under this name describes a different form of the peptide. It is basic, with its arginines and lysines clustered in the middle of the sequence. The methionine at position 17 can oxidize to the sulfoxide, which HPLC separates as a distinct peak, and mass spectrometry confirms the intact amidated peptide. It is supplied as a lyophilized powder in a sealed vial.
What the published research covers
VIP acts at the VPAC1 and VPAC2 receptors and has been studied for its effects on smooth muscle, blood vessels and immune cells. Aviptadil has been tested in clinical trials of lung conditions.
Vasoactive intestinal peptide was isolated from hog small intestine by Sami Said and Viktor Mutt, who in 1970 described a 28-residue polypeptide with systemic vasodilator, cardiac, respiratory and glycemic effects that was chemically distinct from secretin and glucagon (Said, 1970). It was later found throughout the central and peripheral nervous system and on immune cells, and it acts through two G protein-coupled receptors, VPAC1 and VPAC2.
In mice with experimentally induced arthritis, VIP reduced the incidence and severity of disease, prevented joint swelling and the destruction of cartilage and bone, and downregulated both the inflammatory and the autoimmune components of the disease (Delgado, 2001). In primary pulmonary hypertension, a Vienna group reported a deficiency of VIP in the serum and lung tissue of patients, with upregulated receptors, and recorded lower mean pulmonary artery pressure and higher cardiac output in eight patients who received the peptide (Petkov, 2003). A later study of 20 patients with pulmonary hypertension measured the effect of a single inhaled administration of aviptadil during right-heart catheterization and reported a small, short-lived, selective pulmonary vasodilation (Leuchte, 2008). During the COVID-19 pandemic, intravenous aviptadil was tested in hospitalized adults with acute hypoxemic respiratory failure. In the TESICO trial, funded by the National Institutes of Health, 461 participants received aviptadil or placebo; the arm was stopped for futility, the day-90 outcome did not differ significantly, and cumulative mortality to day 90 was 38% with aviptadil and 36% with placebo (Brown, 2023).
The early human studies of VIP were small and mostly uncontrolled, and the one large placebo-controlled trial, in COVID-19 respiratory failure, did not show a benefit. The immune findings come mainly from mouse models and have not been matched by controlled human trials. Natural VIP is broken down quickly by peptidases, which complicates the interpretation of studies that measure its effects in living animals or people.
Regulatory status
Not approved by the FDA for any use. Supplied for laboratory research only.
Testing and documentation
Identity is confirmed by mass spectrometry and purity by HPLC. The certificate of analysis for the batch is reachable from the code on the vial.
Questions laboratories ask
- What strengths is VIP offered in?
- Vials of 10 mg, as listed on the product page. The amount is on the vial label and on the certificate of analysis for the batch.
- Is this aviptadil, the medicine?
- No. Aviptadil is the name given to synthetic VIP in clinical research and, in combination with another drug, in a prescription product authorized in some European countries. It is not approved by the FDA. This material is a research peptide, supplied for laboratory research only; it is not a medicinal product.
- How is a batch tested?
- By an independent laboratory: identity by mass spectrometry and purity by HPLC. The QR code on the vial opens the certificate of analysis for that exact batch; no account is needed to read it.
- Who can order, and how does it ship?
- Orders are accepted under the Research Use Agreement, reaffirmed with every order. Orders ship from Montana, the next business day when paid by card, to United States addresses only and not to freight forwarders.
References
- Said SI et al. (1970). Polypeptide with broad biological activity: isolation from small intestine. Science. PubMed 5450698
- Delgado M et al. (2001). Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nature Medicine. PubMed 11329057
- Petkov V et al. (2003). Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. The Journal of Clinical Investigation. PubMed 12727925
- Leuchte HH et al. (2008). Inhalation of vasoactive intestinal peptide in pulmonary hypertension. The European Respiratory Journal. PubMed 18978135
- Brown SM et al. (2023). Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial. The Lancet Respiratory Medicine. PubMed 37348524
How it ships
Ordering
Ordering needs an account. A retail account opens as soon as you request it and costs nothing. You pay by card at checkout, or by invoice before the order ships. A wholesale account is reviewed before it opens.
Research use only
This product is a research chemical sold solely for in-vitro laboratory research by qualified persons. It is not a drug, food, supplement or cosmetic, has not been evaluated by the FDA, and must not be administered to any person or animal. Read the full agreement